Benign Prostatic Hyperplasia Treatment Market
Benign Prostatic Hyperplasia Treatment Market By Treatment (Drug Classes (Alpha Blockers, 5-Alpha-reductase Inhibitors (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitors), Minimally-invasive Surgeries), By Laser Therapy, By End user & By Region - Global Market Insights 2022-2032
Analysis of Benign Prostatic Hyperplasia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Assumptions and Acronyms Used 2.2. Research Methodology 3. Executive Summary 3.1. Global Market Size (US$ Mn) and Distribution, by Region, 2022 and 2032 3.2. Global Treatment Market: Market Snapshot 4. Market Overview 4.1. Global Market: Treatment Overview 4.2. Global Market: Key Industry Developments 4.3. Market Dynamics 4.4. Drivers and Restraints Snapshot Analysis 4.5. Drivers 4.5.1. Increasing Aging Men Population All Over the World 4.5.2. Expanding Patient Pool Due to Other Risk Factors 4.6. Restraints 4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition 4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs 4.7. Opportunities 4.8. Global Market Revenue Projections (US$ Mn), 2022-2032 5. Key Insights 5.1. Clinical Trial Pipeline Analysis 5.2. U.S. Prevalence of Benign Prostatic Hyperplasia 5.3. Re-imbursement Scenario 5.4. Key Merger and Acquisitions 5.5. Number of Surgeries (Unit Procedures) Performed (2019) 5.6. Competitive Market Share Analysis By Company (2019) 5.7. Average Cost of Benign Prostatic Hyperplasia (BPH) Treatment 5.8. Product/Brand Analysis - 2018 5.8.1. Urolift 5.8.2. Rezum 6. Global Market Analysis, by Treatment 6.1. Introduction 6.2. Global Market Size and Forecast, by Treatment 6.2.1. Drug Class 6.2.1.1. Alpha-Blockers 6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor 6.2.1.4. Others 6.2.2. Minimally Invasive Surgeries 6.2.2.1. Transurethral resection of the prostate (TURP) 6.2.2.2. Transurethral incision of the prostate (TUIP) 6.2.2.3. Robotic Surgeries 6.2.2.4. Transurethral microwave thermotherapy (TUMT) 6.2.2.5. Prostatic Urethral lift 6.2.2.6. Others 6.2.3. Laser Therapy 6.2.4. Others 6.3. Global Market Analysis, by Treatment 6.4. Global Market Attractiveness Analysis, by Treatment 7. Global Market Analysis, by End-user 7.1. Introduction 7.2. Global Market Size and Forecast, by End-user 7.2.1. Hospitals 7.2.2. Ambulatory Surgical Centers 7.2.3. Specialty Clinics 7.2.4. Others 7.3. Global Market Analysis, by End-user 7.4. Global Market Attractiveness Analysis, by End-user 8. Global Market Analysis, by Region 8.1. Global Market Size and Forecast, by Region, 2022-2032 8.1.1. North America 8.1.2. Europe 8.1.3. Asia Pacific 8.1.4. Latin America 8.1.5. Middle East & Africa 8.2. Global Market Analysis, by Region 8.3. Global Market Attractiveness Analysis, by Region 9. North America Market Analysis 9.1. North America Market 9.2. North America Market Overview 9.3. North America Market Size and Forecast, by Treatment 9.3.1. Drug Class 9.3.1.1. Alpha-Blockers 9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor 9.3.1.4. Others 9.3.2. Minimally Invasive Surgeries 9.3.2.1. Transurethral resection of the prostate (TURP) 9.3.2.2. Transurethral incision of the prostate (TUIP) 9.3.2.3. Robotic Surgeries 9.3.2.4. Transurethral microwave thermotherapy (TUMT) 9.3.2.5. Prostatic Urethral lift 9.3.2.6. Others 9.3.3. Laser Therapy 9.3.4. Others 9.4. North America Market Size and Forecast, by End-user 9.4.1. Hospitals 9.4.2. Ambulatory Surgical Centers 9.4.3. Specialty Clinics 9.4.4. Others 9.5. North America Market Forecast, by Country 9.5.1. U.S. 9.5.2. Canada 9.6. North America Market Attractiveness Analysis 9.6.1. By Treatment 9.6.2. By End-user 9.6.3. By Country 10. Europe Market Analysis 10.1. Europe Market 10.2. Europe Market Overview 10.3. Europe Market Size and Forecast, by Treatment 10.3.1. Drug Class 10.3.1.1. Alpha-Blockers 10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor 10.3.1.4. Others 10.3.2. Minimally Invasive Surgeries 10.3.2.1. Transurethral resection of the prostate (TURP) 10.3.2.2. Transurethral incision of the prostate (TUIP) 10.3.2.3. Robotic Surgeries 10.3.2.4. Transurethral microwave thermotherapy (TUMT) 10.3.2.5. Prostatic Urethral lift 10.3.2.6. Others 10.3.3. Laser Therapy 10.3.4. Others 10.4. Europe Market Size and Forecast, by End-user 10.4.1. Hospitals 10.4.2. Ambulatory Surgical Centers 10.4.3. Specialty Clinics 10.4.4. Others 10.5. Europe Market Forecast, by Country/Sub-region 10.5.1. U.K. 10.5.2. France 10.5.3. Germany 10.5.4. Spain 10.5.5. Italy 10.5.6. Rest of Europe 10.6. Europe Market Attractiveness Analysis 10.6.1. By Treatment 10.6.2. By End-user 10.6.3. By Country/Sub-region 11. Asia Pacific Market Analysis 11.1. Asia Pacific Market Key Findings 11.2. Asia Pacific Market Overview 11.3. Asia Pacific Market Size and Forecast, by Treatment 11.3.1. Drug Class 11.3.1.1. Alpha-Blockers 11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor 11.3.1.4. Others 11.3.2. Minimally Invasive Surgeries 11.3.2.1. Transurethral resection of the prostate (TURP) 11.3.2.2. Transurethral incision of the prostate (TUIP) 11.3.2.3. Robotic Surgeries 11.3.2.4. Transurethral microwave thermotherapy (TUMT) 11.3.2.5. Prostatic Urethral lift 11.3.2.6. Others 11.3.3. Laser Therapy 11.3.4. Others 11.4. Asia Pacific Market Size and Forecast, by End-user 11.4.1. Hospitals 11.4.2. Ambulatory Surgical Centers 11.4.3. Specialty Clinics 11.4.4. Others 11.5. Asia Pacific Market Forecast, by Country/Sub-region 11.5.1. China 11.5.2. India 11.5.3. Japan 11.5.4. Australia & New Zealand 11.5.5. Rest of Asia Pacific 11.6. Asia Pacific Market Attractiveness Analysis 11.6.1. By Treatment 11.6.2. By End-user 11.6.3. By Country/Sub-region 12. Latin America Market Analysis 12.1. Latin America Market Key Findings 12.2. Latin America Market Overview 12.3. Latin America Market Size and Forecast, by Treatment 12.3.1. Drug Class 12.3.1.1. Alpha-Blockers 12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor 12.3.1.4. Others 12.3.2. Minimally Invasive Surgeries 12.3.2.1. Transurethral resection of the prostate (TURP) 12.3.2.2. Transurethral incision of the prostate (TUIP) 12.3.2.3. Robotic Surgeries 12.3.2.4. Transurethral microwave thermotherapy (TUMT) 12.3.2.5. Prostatic Urethral lift 12.3.2.6. Others 12.3.3. Laser Therapy 12.3.4. Others 12.4. Latin America Market Size and Forecast, by End-user 12.4.1. Hospitals 12.4.2. Ambulatory Surgical Centers 12.4.3. Specialty Clinics 12.4.4. Others 12.5. Latin America Market Forecast, by Country/Sub-region 12.5.1. Brazil 12.5.2. Mexico 12.5.3. Rest of Latin America 12.6. Latin America Market Attractiveness Analysis 12.6.1. By Treatment 12.6.2. By End-user 12.6.3. By Country/Sub-region 13. Middle East & Africa Market Analysis 13.1. Middle East & Africa Market 13.2. Market Overview 13.3. Middle East & Africa Market Size and Forecast, by Treatment 13.3.1. Drug Class 13.3.1.1. Alpha-Blockers 13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs) 13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor 13.3.1.4. Others 13.3.2. Minimally Invasive Surgeries 13.3.2.1. Transurethral resection of the prostate (TURP) 13.3.2.2. Transurethral incision of the prostate (TUIP) 13.3.2.3. Robotic Surgeries 13.3.2.4. Transurethral microwave thermotherapy (TUMT) 13.3.2.5. Prostatic Urethral lift 13.3.2.6. Others 13.3.3. Laser Therapy 13.3.4. Others 13.4. Middle East & Africa Market Size and Forecast, by End-user 13.4.1. Hospitals 13.4.2. Ambulatory Surgical Centers 13.4.3. Specialty Clinics 13.4.4. Others 13.5. Middle East & Africa Market Forecast, by Country/Sub-region 13.5.1. GCC Countries 13.5.2. South Africa 13.5.3. Rest of Middle East & Africa 13.6. Middle East & Africa Market Attractiveness Analysis 13.6.1. By Treatment 13.6.2. By End-user 13.6.3. By Country/Sub-region 14. Competition Landscape (Pharmaceutical Companies) 14.1. Company Profiles 14.1.1. Abbott 14.1.1.1. Overview (HQ, Employee Strength, Business Segments) 14.1.1.2. Financials 14.1.1.3. Recent Developments 14.1.1.4. Strategy 14.1.2. Allergan Plc 14.1.2.1. Overview (HQ, Employee Strength, Business Segments) 14.1.2.2. Financials 14.1.2.3. Recent Developments 14.1.2.4. Strategy 14.1.3. Astellas Pharma, Inc. 14.1.3.1. Overview (HQ, Employee Strength, Business Segments) 14.1.3.2. Financials 14.1.3.3. Recent Developments 14.1.3.4. Strategy 14.1.4. Asahi Kasei Corporation 14.1.4.1. Overview (HQ, Employee Strength, Business Segments) 14.1.4.2. Financials 14.1.4.3. Recent Developments 14.1.4.4. Strategy 14.1.5. Boehringer Ingelheim GmbH 14.1.5.1. Overview (HQ, Employee Strength, Business Segments) 14.1.5.2. Financials 14.1.5.3. Recent Developments 14.1.5.4. Strategy 14.1.6. GlaxoSmithKline Plc. 14.1.6.1. Overview (HQ, Employee Strength, Business Segments) 14.1.6.2. Financials 14.1.6.3. Recent Developments 14.1.6.4. Strategy 14.1.7. Pfizer, Inc. 14.1.7.1. Overview (HQ, Employee Strength, Business Segments) 14.1.7.2. Financials 14.1.7.3. Recent Developments 14.1.7.4. Strategy 14.1.8. Sanofi SA 14.1.8.1. Overview (HQ, Employee Strength, Business Segments) 14.1.8.2. Financials 14.1.8.3. Recent Developments 14.1.8.4. Strategy 14.1.9. Teva Pharmaceutical Industries Ltd. 14.1.9.1. Overview (HQ, Employee Strength, Business Segments) 14.1.9.2. Financials 14.1.9.3. Recent Developments 14.1.9.4. Strategy 14.1.10. Merck & Co., Inc. 14.1.10.1. Overview (HQ, Employee Strength, Business Segments) 14.1.10.2. Financials 14.1.10.3. Recent Developments 14.1.10.4. Strategy 15. Competition Landscape (Medical Devices/Service Provider Organizations) 15.1. Company Profiles 15.1.1. Boston Scientific Corporation 15.1.1.1. Overview (HQ, Employee Strength, Business Segments) 15.1.1.2. Financials 15.1.1.3. Recent Developments 15.1.1.4. Strategy 15.1.2. Teleflex Incorporated 15.1.2.1. Overview (HQ, Employee Strength, Business Segments) 15.1.2.2. Financials 15.1.2.3. Recent Developments 15.1.2.4. Strategy 15.1.3. Endo International Plc. 15.1.3.1. Overview (HQ, Employee Strength, Business Segments) 15.1.3.2. Financials 15.1.3.3. Recent Developments 15.1.3.4. Strategy 15.1.4. Urologix, LLC 15.1.4.1. Overview (HQ, Employee Strength, Business Segments) 15.1.4.2. Financials 15.1.4.3. Recent Developments 15.1.4.4. Strategy 15.1.5. LISA Laser 15.1.5.1. Overview (HQ, Employee Strength, Business Segments) 15.1.5.2. Financials 15.1.5.3. Recent Developments 15.1.5.4. Strategy 15.1.6. Olympus 15.1.6.1. Overview (HQ, Employee Strength, Business Segments) 15.1.6.2. Financials 15.1.6.3. Recent Developments 15.1.6.4. Strategy
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 01: Prostate Cancer Therapeutics: Pipeline Analysis – Phase III (1/2)
TABLE 02: Prostate Cancer Therapeutics: Pipeline Analysis – Phase III (2/2)
TABLE 03: Prostate Cancer Therapeutics: Pipeline Analysis – Phase II (1/2)
TABLE 04: Prostate Cancer Therapeutics: Pipeline Analysis – Phase II (2/2)
TABLE 05: Prostate Cancer Therapeutics: Pipeline Analysis – Phase I
TABLE 06: 2015 Patient Population Break Down
TABLE 07: Number of Surgeries (Unit Procedures) Performed in United States (2022)
TABLE 08: Summary of Current BPH Treatments in U.S.
TABLE 09: Global Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 10: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 11: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 12: Global Market Size (US$ Mn) Forecast, by End-user, 2022-2032
TABLE 13: Global Market Value (US$ Mn) Forecast, by Region, 2022-2032
TABLE 14: North America Market Value (US$ Mn) Forecast, by Country, 2022-2032
TABLE 15: Global Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 16: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 17: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 18: North America Market Value (US$ Mn) Forecast, by End-user, 2022-2032
TABLE 19: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
TABLE 20: Europe Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 21: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 22: Europe Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 23: Europe Market Value (US$ Mn) Forecast, by End-user, 2022-2032
TABLE 24: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
TABLE 25: Asia Pacific Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 26: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 27: Asia Pacific Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 28: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2022-2032
TABLE 29: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
TABLE 30: Latin America Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 31: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 32: Latin America Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 33: Latin America Market Value (US$ Mn) Forecast, by End-user, 2022-2032
TABLE 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
TABLE 35: Middle East & Africa Market Size (US$ Mn) Forecast, by Treatment, 2022-2032
TABLE 36: Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
TABLE 37: Middle East & Africa Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032
TABLE 38: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 01: Global Market Size (US$ Mn) Forecast, 2022-2032
FIG. 02: Global Market Value Share, by Treatment, 2021
FIG. 03: Global Market Value Share, by Drug Class, 2021
FIG. 04: Global Market Value Share, by End-user, 2021
FIG. 05: Global Market Value Share, by Minimally Invasive Surgery, 2021
FIG. 06: Global Market Value Share Analysis, by Treatment, 2022 & 2032
FIG. 07: Global Market Revenue, by Drug Class, 2022-2032
FIG. 08: Global Market Revenue, by Minimally Invasive Surgeries, 2022-2032
FIG. 09: Global Market Revenue, by Laser Therapy, 2022-2032
FIG. 10: Global Market Revenue, by Others, 2022-2032
FIG. 11: Global Market Attractiveness Analysis, by Treatment, 2022-2032
FIG. 12: Global Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 13: Global Market Revenue, by Hospitals, 2022-2032
FIG. 14: Global Market Revenue, by Ambulatory Surgical Centers, 2022-2032
FIG. 15: Global Market Revenue, by Specialty Clinics, 2022-2032
FIG. 16: Global Market Revenue, by Others, 2022-2032
FIG. 17: Global Market Attractiveness Analysis, by End-user, 2022-2032
FIG. 18: Global Market Value Share (%), by Region, 2018 and 2026
FIG. 19: Global Market Attractiveness, by Region, 2022-2032
FIG. 20: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032
FIG. 21: North America Market Value Share, by Country, 2022 & 2032
FIG. 22: North America Market Attractiveness, by Country, 2022-2032
FIG. 23: North America Market Value Share Analysis, by Product, 2022 & 2032
FIG. 24: North America Market Attractiveness, by Product, 2022-2032
FIG. 25: North America Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 26: North America Market Attractiveness, by End-user, 2022-2032
FIG. 27: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032
FIG. 28: Europe Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 29: Europe Market Attractiveness, by Country/Sub-region, 2022-2032
FIG. 30: Europe Market Value Share Analysis, by Product, 2022 & 2032
FIG. 31: Europe Market Attractiveness, by Product, 2022-2032
FIG. 32: Europe Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 33: Europe Market Attractiveness, by End-user, 2022-2032
FIG. 34: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032
FIG. 35: Asia Pacific Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 36: Asia Pacific Market Attractiveness, by Country/Sub-region, 2022-2032
FIG. 37: Asia Pacific Market Value Share Analysis, by Product, 2022 & 2032
FIG. 38: Asia Pacific Market Attractiveness, by Product, 2022-2032
FIG. 39: Asia Pacific Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 40: Asia Pacific Market Attractiveness, by End-user, 2022-2032
FIG. 41: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032
FIG. 42: Latin America Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 43: Latin America Market Attractiveness, by Country/Sub-region, 2022-2032
FIG. 44: Latin America Market Value Share Analysis, by Product, 2022 & 2032
FIG. 45: Latin America Market Attractiveness, by Product, 2022-2032
FIG. 46: Latin America Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 47: Latin America Market Attractiveness, by End-user, 2022-2032
FIG. 48: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032
FIG. 49: Middle East & Africa Market Value Share, by Country/Sub-region, 2022 & 2032
FIG. 50: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2022-2032
FIG. 51: Middle East & Africa Market Value Share Analysis, by Product, 2022 & 2032
FIG. 52: Middle East & Africa Market Attractiveness, by Product, 2022-2032
FIG. 53: Middle East & Africa Market Value Share Analysis, by End-user, 2022 & 2032
FIG. 54: Middle East & Africa Market Attractiveness, by End-user, 2022-2032
FIG. 55: Global Devices Market Share Analysis, by Company (2019)
FIG. 56: GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 57: GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2017-2021
FIG. 58: GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
FIG. 59: GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
FIG. 60: Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 61: Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
FIG. 62: Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 63: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 64: Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
FIG. 65: Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 66: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
FIG. 67: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 68: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
FIG. 70: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
FIG. 71: Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 72: Abbott Laboratories R&D Intensity and Sales & Marketing Intensity – Company Level, 2017-2021
FIG. 73: Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
FIG. 74: Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
FIG. 75: Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 76: Allergan plc Breakdown of Net Sales (%), by Geography, 2018
FIG. 77: Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2017-2021
FIG. 78: Allergana plc Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 79: Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 80: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
FIG. 81: Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2017-2021
FIG. 82: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
FIG. 83: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 84: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
FIG. 85: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
FIG. 86: Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2017-2021
FIG. 87: Merck & Co., Inc. Break-up of Net Sales, by Region, 2021
FIG. 88: Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 89: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2017-2021
FIG. 90: Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 91: Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 92: Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 93: Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 94: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2021
FIG. 95: Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2017-2021
FIG. 96: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2021
FIG. 97: Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 98: Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2021
FIG. 99: Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2021
FIG. 100: Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 101: Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2021
FIG. 102: Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
FIG. 103: Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021
FIG. 104: Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021
FIG. 105: Olympus Corporation Breakdown of Net Sales (%), by Region, 2021
FIG. 106: Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request